U.S. natural gas prices upside likely in 2026 - Morgan Stanley
DUBLIN, Ohio - Cardinal Health (NYSE:CAH), a prominent $30.5 billion healthcare provider with "GREAT" financial health according to InvestingPro analysis, has expanded its Board of Directors with the appointment of two new independent directors, Robert Musslewhite and Sudhakar Ramakrishna, effective last Monday. The announcement was made today, reflecting the company’s commitment to integrating advanced analytics and cybersecurity expertise into its governance.
Musslewhite, with a history of leadership in technology-oriented healthcare companies, adds significant experience to Cardinal Health’s board, particularly in the strategic use of data across healthcare systems. His background includes serving as CEO of Definitive Healthcare Corp. and OptumInsight, and he currently advises a private equity firm. Musslewhite’s educational credentials include a degree in Economics from Princeton University and a law degree from Harvard Law School. He will join the Audit and Human Resources and Compensation Committees.
Ramakrishna, currently the President and CEO of SolarWinds Corporation, brings over two decades of technology and business expertise, with a focus on cybersecurity and crisis management. His previous roles span various senior leadership positions at technology firms including Pulse Secure, LLC, and Citrix Systems, Inc. Ramakrishna holds a Bachelor of Engineering from Osmania University and advanced degrees in Computer Science and Management from Kansas State University and Northwestern University, respectively. He will serve on the Audit and Risk Oversight Committees.
Gregory Kenny, Chairman of the Board for Cardinal Health, praised the new appointees for their ability to drive growth and innovation in complex business environments. Jason Hollar, CEO of Cardinal Health, emphasized the alignment of the new directors’ experience and leadership with the company’s culture and the value they will add in navigating evolving markets.
Cardinal Health, a global distributor of pharmaceuticals and medical products generating over $222 billion in annual revenue, continues to focus on customer-centric solutions and innovation. The addition of Musslewhite and Ramakrishna to the board is anticipated to bolster the company’s strategic direction in an increasingly technology-driven healthcare landscape. With net income growth expected this year and trading at attractive valuations relative to its growth potential, Cardinal Health appears well-positioned for future expansion. For detailed analysis and 12 additional key insights about Cardinal Health, including Fair Value estimates and growth projections, explore the comprehensive Pro Research Report available on InvestingPro. This news is based on a press release statement from Cardinal Health.
In other recent news, Cardinal Health has reported its second-quarter earnings for fiscal year 2024, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $1.93, exceeding the forecasted $1.77, and generated $55.3 billion in revenue, surpassing the expected $54.56 billion. Despite these positive results, the company saw a slight dip in its stock value. Cardinal Health has raised its full-year EPS guidance to a range of $7.85 to $8.00, reflecting confidence in continued growth. Jefferies analyst Brian Tanquilut upgraded Cardinal Health stock from Hold to Buy, setting a new price target of $150, citing the company’s impressive management and future earnings potential. The upgrade also highlights Cardinal Health’s limited exposure to healthcare distribution center overhangs compared to its peers. Additionally, the company is investing in automation and domestic manufacturing to bolster its operations. These developments indicate a positive outlook for Cardinal Health amidst a robust performance in the specialty distribution market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.